Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III trial of MK-5172 + MK-8742 in chronic hepatitis C patients with inherited blood disorders, with or without HIV co-infection
2014-002356-27Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Aug 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, double-blind trial of grazoprevir and verubecestat in hepatitis C virus infection (2 arms), sponsored by Merck & Co. Primary endpoint: SVR12 rate. Started Aug 2014; status: completed.
02
Drugs
grazoprevirverubecestat
03
Conditions
hepatitis C virus infection
Beyond the preview
Go deeper on 2014-002356-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-002356-27.